Sobi buys rare-disease drug emapalumab, zooms in on hematology and immunology
Rare diseases specialist Swedish Orphan Biovitrum (Sobi) has agreed to buy the drug emapalumab and is reorganizing to increase focus on late-stage development in hematology and immunology.
from Reuters: Health News https://reut.rs/2KKpHUs
http://bit.ly/2zwRqiM